A transdisciplinary exploration of synergies and crossroads in psychedelic research and therapy
Full schedule and Call for Speakers here.

Join us for a day on the integration of research across disciplines and practice, and explore with us innovative tools to solve some of the complex problems of today.

The uniMIND Symposium is a hybrid event that takes place online via Zoom and on-site at Maastricht University. Online participation is entirely free. On site tickets are limited and cost 10 Euros to refinance the event. Invitation links will be sent via mail to all registered guests.

Depending on the pandemic situation, we will start with a 50 person on site registration and may extend to a total of 150 guests. If you would like to join on site but are uncertain given the present conditions or if all seats are already booked, please register for online participation and check yes at “Add me to the waiting list”.

Concerning on site participation, the local Covid 19-protection rules apply. We’ll keep you updated with any changes.

On-site and online registration are possible:

To attend online, please register via THIS FORM.

For on-site registration, please buy your tickets below. Any money generated through ticket sales or donations will be used exclusively to refinance the event. Please consider donating to help us promote young talents in psychedelic research.

 

Exploring structures and processes emerging around psychedelic research

Join us for a day on the integration of research across disciplines and practice, and explore with us innovative tools to solve some of the complex problems of today.

The event is all-free and will take place via Zoom. Invitation links will be sent via mail to all registered guests (RSVP below).

With

and

Full schedule and Call for Speakers here.

Link to join Webinar

https://us02web.zoom.us/j/89167259444

 

Already in the early years of the new millennium, Prof. Evgeny Krupitsky and his team used Ketamine in the treatment of opioid addiction in pioneering clinical studies. In one of these projects, seventy detoxified opioid addicts received either a low, sub-psychedelic dose of Ketamine or a high, psychedelic dose of Ketamine, both supported by accompanying psychotherapy in a randomized trial. Prof. Kupitsky will talk about the implications and results for his groundbreaking work that will inspire other clinicians in the years to come.

Oft sprechen Depressionen nicht auf erste Behandlungsansätze an, woraufhin von einer „therapieresistenten“ Depression gesprochen wird. Der Vortrag zeigt auf, dass es allerdings entgegen der semantischen Bedeutung der „Therapieresistenz“ ein weites Spektrum an weiteren wirksamen Behandlungsoptionen gibt. Diese umfassen medikamentöse, psychotherapeutische und verschiedene somatische Strategien, unter welchen auch dem Ketamin eine neue Bedeutung zukommt.

 

Dr. Levine will provide an overview of the early translation of research on ketamine for depression to real-world applications in private clinics across the United States, its evolution over the past decade, and implications as a new model of psychiatric care delivery.

Sind LSD, MDMA & Psilocybin neue Substanzen in der Behandlung seelischer Erkrankungen? 

Die Anwendung von Psychedelika in der Psychotherapie ist keine neue Erfindung. Bereits vor 80 Jahren entdeckten TherapeutInnen diese Substanzklasse, die in der Lage ist, das Bewusstsein in einer besonderen Art zu verändern. 

Seit den 90er–Jahren erleben wir ein Wiederaufleben der psychedelischen Forschung. Die Menge an wissenschaftlichen Studien mit positiven Ergebnissen für die Behandlung von Depressionen, posttraumatischen Belastungsstörungen und Angstzuständen mit Psychedelika nimmt mit jedem Jahr zu. 

In diesem Vortrag wird Sergio Pérez (MIND Academy Director) Ihnen einen Überblick über den Stand der Forschung, sowie Hoffnungen und Grenzen dieser Substanzklasse präsentieren.